A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. 8 Conversely, 1 dose of Andexxa will typically cost between 24,750 and 49,500 alone it does not need to be administered alongside PCC or aPCC. Anticoagulant reversal for life-threatening bleeds.FDA approved in May 2018, limited availability June 2018 with broader commercial launch in early 2019.Inhibits the activity of the Tissue Factor Pathway Inhibitor (TFPI), increasing tissue factor-initiated thrombin generation.

Binds and sequesters factor Xa inhibitors.Dosage Forms: solution reconstituted, 100 mg per vialĪdult Dosing Determined by last dose, type of factor Xa inhibitor, and dose of inhibitorĤ00 mg IV bolus at rate of ~30 mg/minute, followed 2 minutes later by 4 mg/minute for up to 120 minutesĨ00 mg IV bolus at rate of ~30 mg/minute, followed 2 minutes later by 8 mg/minute for up to 120 minutes.Type: factor Xa inhibitor reversal, antidote.

2.1 Determined by last dose, type of factor Xa inhibitor, and dose of inhibitor.

Andexxa dosing